ICAD241018C2500
- 0.05
- 0.000.00%
iCAD Inc Newsroom
ICAD to Participate in the IAccess Alpha Buyside Best Ideas Fall Conference 2024
Lexaria Bioscience Taps InVivo Therapeutics CFO Richard Christopher As New CEO
The Market Lifts ICAD, Inc. (NASDAQ:ICAD) Shares 29% But It Can Do More
iCAD Inc | 10-Q/A: Quarterly report (Amendment)
iCAD Inc | 10-Q: Q2 2024 Earnings Report
Icad Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Revenue Results
BTIG Maintains ICAD Inc(ICAD.US) With Buy Rating, Maintains Target Price $3
BTIG analyst Marie Thibault maintains $iCAD Inc(ICAD.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 32.4% and a total
Earnings Call Summary | ICAD Inc(ICAD.US) Q2 2024 Earnings Conference
Icad Q2 2024 GAAP EPS $(0.07), Inline, Sales $5.00M Beat $4.42M Estimate
Earnings Flash (ICAD) ICAD Reports Q2 Revenue $5M, Vs. Street Est of $4.4M
Earnings Flash (ICAD) ICAD Reports Q2 Loss $-0.07, Vs. Street Est of $-0.07
Express News | ICAD Inc - Believes It Has Sufficient Cash Resources to Fund Its Planned Operations With No Need to Raise Additional Funding
Express News | ICAD, Inc. Q2 Gross Profit USD 4.2 Million
Express News | ICAD, Inc. Q2 Operating Expenses USD 6.2 Million
Express News | ICAD, Inc. Q2 Revenue USD 5 Million
Express News | ICAD Reports Financial Results for Second Quarter Ended June 30, 2024
ICAD 2Q Loss/Shr 6c >ICAD
ICAD 2Q Loss $1.71M >ICAD
Craig-Hallum Maintains ICAD Inc(ICAD.US) With Buy Rating
Craig-Hallum analyst Per Ostlund maintains $iCAD Inc(ICAD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -17.2% over the
ICAD to Report Second Quarter 2024 Financial Results on August 13, 2024